The Next Industry to Bow to Trump
Briefly

The Next Industry to Bow to Trump
"Donald Trump, always one to tout his knack for dealmaking, declared on Tuesday that he'd just struck one of his best deals ever. "This is one of the biggest medical announcements that this office has ever made," Trump said in the Oval Office, flanked by his top health officials. They'd gathered to announce that the administration had cut a deal with the pharmaceutical giant Pfizer. Trump couldn't help but smirk. "I'm surprised you're agreeing to this," he told Albert Bourla, the CEO of Pfizer."
"Even drug-industry lobbyists are reportedly surprised by what Pfizer agreed to. The company has a history of outmaneuvering Trump's attempts to lower drug costs, yet it pledged to cut the costs of its drugs in the United States to match the lower prices it charges other developed countries. Pfizer also agreed to participate in TrumpRx, a new website the administration announced on Tuesday that will allow Americans to buy certain drugs at steep discounts."
"In his first press conference as president-elect in 2017, Trump declared that drugmakers were "getting away with murder." By the end of Trump's first month in office, he had summoned pharmaceutical executives to the White House to needle them about the issue. "I think you people know very well, it's very unfair to this country," he told them. He spent much of his first term unveiling policy after policy meant to reduce what Americans pay for prescription drugs."
A deal with Pfizer will lower U.S. drug prices to match rates charged in other developed countries. Pfizer will participate in TrumpRx, a new website offering Americans the ability to buy certain drugs at steep discounts. Drug-industry lobbyists expressed surprise at Pfizer's agreement given the company's history of resisting efforts to reduce U.S. drug costs. A decade-long campaign targeted pharmaceutical price disparities, including a 2017 press conference that labeled drugmakers 'getting away with murder' and a White House meeting that questioned industry executives. Multiple policy initiatives aimed to reduce prescription-drug spending met repeated failures before this pact.
Read at The Atlantic
Unable to calculate read time
[
|
]